Moderna Stock Rises After Positive News on Cancer Vaccine
Aufgrund positiver Ergebnisse aus einer Phase-3-Studie für einen personalisierten Krebsimpfstoff, entwickelt mit Merck, stieg die Moderna-Aktie um fast 130%. Der Impfstoff „Intismeran autogene“ zeigte in der Kombination mit Keytruda eine signifikante Reduktion des Rückfall- oder Todesrisikos bei Patienten mit maligne Melanome, was Experten als großen Durchbruch für das Unternehmen wertet.
Moderna's shares experienced a dramatic increase after positive results were announced from a Phase 3 study for a personalized cancer vaccine that the company developed in collaboration with Merck. This vaccine, called "Intismeran autogene," is tailored to consider the genetic structure of the tumor. The study included 1100 patients with malignant melanomas. The combination of the vaccine with Keytruda significantly reduced the risk of relapse or death. Experts see this result as a major breakthrough for Moderna's future market role, which is why the Moderna stock price rose by almost 130%.